Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222
01 sept. 2020 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics
03 août 2020 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics Oxford, UK – 3 August...
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
08 juin 2020 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Interim Results
04 sept. 2019 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019 Oxford, UK – 4 September 2019: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell...
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
26 mars 2019 08h00 HE
|
Oxford BioMedica plc
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia Oxford, UK – 26 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene...
Oxford Biomedica plc: Preliminary results for the year ended 31 December 2018
14 mars 2019 08h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2018 Delivery of dual strategy leads to strong financial growth Oxford, UK – 14 March 2019: Oxford Biomedica plc (LSE: OXB),...